Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in the company ...

Sanofi relocated 2,000 employees to a new $130M Morristown flagship office at M Station West in May, leaving Bridgewater.

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

From my colleague Adam Feuerstein: French drug maker Sanofi is acquiring the small biotech Vigil Neuroscience for $470 ...

Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) ...

Sanofi has agreed to acquire Vigil Neuroscience in a cash transaction with an equity... DUBLIN The Iseq All Share opened in the red on Thursday, falling 0.34 per cent (-39.24bps)... Jakob Stausholm, ...

The French drugmaker joined several peers in promising new investments in U.S. drug production, but cautioned plans could ...

Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational ...

Sanofi SA said it will invest at least $20 billion in the US through 2030, joining other European pharmaceutical companies ...

Global healthcare company Sanofi yesterday formally opened its new flagship US offices at M Station West in Morristown.